Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PT-112 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PT-112 in combination with avelumab | EXPERIMENTAL | PT-112, administered by intravenous infusion avelumab, administered by intravenous infusion Patients with all listed conditions are eligible for treatment during the dose escalation phase of the study. Patients with NSCLC are eligible for the dose confirmation phase of the study. |
| Name | Type | Description |
|---|---|---|
| PT-112 | DRUG | The RP2D of PT-112 when used in combination with avelumab has been determined during dose escalation and is being confirmed in the NSCLC dose confirmation cohort. For the NSCLC confirmation cohort, PT-112 will be administered at a dose of 360 mg/m2 on Days 1, 8 and 15. |
| avelumab | BIOLOGICAL | Avelumab will be administered at a fixed dose of 800 mg on Days 1 and 15. |
Key Inclusion Criteria: 1. Histologically or cytologically confirmed metastatic or locally advanced, squamous or non-squamous NSCLC (NSCLC). Patients must have received no more than four prior lines of therapy, including a PD-1 / PD-L1-containing therapy and a platinum containing regimen. Patients ...
PT-112 is an investigational small molecule being studied for the treatment of Non-Small Cell Lung Cancer (NSCLC). It is currently in Phase 1 clinical development, meaning it has not yet been approved by regulatory authorities and is still being evaluated for safety and efficacy in patients.
PT-112 is being developed by Pfizer, Inc. (NYSE: PFE). The company is conducting clinical trials to evaluate the drug's potential as a treatment for Non-Small Cell Lung Cancer (NSCLC).
PT-112 is in Phase 1 clinical development. It is an investigational drug being studied for Non-Small Cell Lung Cancer (NSCLC) and has not been approved by the FDA or other regulatory agencies. Its safety and efficacy are still being evaluated in early-stage trials.
PT-112 has been studied in one clinical trial, identified as NCT03409458. This was a Phase 1 dose escalation and confirmation study of PT-112 in combination with avelumab for advanced solid tumors, including Non-Small Cell Lung Cancer (NSCLC). The trial, which enrolled 68 participants, has been completed.
No, PT-112 is not the same as avelumab. PT-112 is an investigational small molecule being developed by Pfizer, while avelumab is a separate cancer immunotherapy. In the clinical trial NCT03409458, PT-112 was studied in combination with avelumab for the treatment of Non-Small Cell Lung Cancer (NSCLC).